Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany: real-world evidence from an administrative database between 2010 and 2019

Jan-Michel Heger; Peter Borchmann; Sybille Riou; Barbara Werner; Michael S Papadimitrious; Jörg Mahlich

doi:10.3389/fonc.2024.1432310

Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany: real-world evidence from an administrative database between 2010 and 2019

Front Oncol. 2024 Oct 9:14:1432310. doi: 10.3389/fonc.2024.1432310. eCollection 2024.

Authors

Jan-Michel Heger¹, Peter Borchmann¹, Sybille Riou², Barbara Werner³, Michael S Papadimitrious², Jörg Mahlich^{2

4}

Affiliations

¹ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany.
² Health Economics and Outcomes Research, Miltenyi Biomedicine, Bergisch Gladbach, Germany.
³ Health Economics and Health Services Research, Team Gesundheit Gesellschaft für Gesunheitsmanagement mbH, Essen, Germany.
⁴ Duesseldorf Institute for Competition Economics (DICE), Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

Abstract

Background: Limited real-world evidence is available for patients with diffuse large B-cell lymphoma (DLBCL) who received an autologous stem cell transplantation (ASCT) in Germany.

Objectives: This study aims to describe the real-world survival outcomes of patients with DLBCL who received ASCT in Germany after diagnosis.

Design: This study is a retrospective database analysis covering the period between 2010 and 2019.

Methods: Unadjusted overall survival (OS) was plotted using the Kaplan-Meier estimator for the overall population and stratified by relapse status. A Cox regression was run to identify factors that influence OS.

Results: A total of 112 patients received an ASCT, with the average time from first-line treatment to ASCT being 11.7 months. The median OS estimated by Kaplan-Meier was 83.4 months for the entire cohort. The only variable that significantly reduced the OS was the presence of subsequent treatment after ASCT in a time-dependent model.

Conclusion: OS after ASCT for DLBCL patients in Germany is higher than previously reported and may still be considered a valid option for carefully selected patients with relapsed/refractory DLBCL.

Keywords: Germany; autologous stem cell transplantation; claims data; diffuse large B-cell lymphoma; real-world evidence; survival.

Grants and funding

The author(s) declare that financial support was received for the research, and publication of this article. This study and the rapid service fee were funded by Miltenyi Biomedicine GmbH. Team Gesundheit Gesellschaft für Gesundheitsmanagement, a contract research company that received funding from Miltenyi Biomedicine to conduct the study in line with the study protocol.